Business
Warrant Exercise
Warrant Exercise.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9837Z ValiRx PLC 20 December 2017 \n\nVALIRX PLC\n(\"ValiRx\" or the \"Company\")\nEXERCISE OF WARRANTS AND ISSUE OF EQUITY\n \n \nLondon, UK., 20 December 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, has received notification of the exercise of warrants over 1,000,000 ordinary shares at an exercise price of 5p in the Company, providing the Company with gross proceeds of £50,000.\n \nApplication will be made to the London Stock Exchange to admit the 1,000,000 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 28 December 2017. The new ordinary shares will rank pari passu with the existing ordinary shares.\n \nFor the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above, in addition to those announced earlier today, the enlarged issued share capital of the Company will comprise 269,545,413 ordinary shares of 0.1 pence each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser) \nLiam Murray/Jo Turner/Richard Nash\n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\n\n\n\n\n\n\n\n\nBeaufort Securities Limited (Broker) \nJon Belliss\n\n\nTel: +44 (0) 207 382 8300\n\n\n\n\n \nNotes for Editors\n \nAbout ValiRx \nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \nThe Comp...